Laddar populära aktier...
Prostatype Genomics har nyligen lanserat sitt test Prostatype® på den viktiga amerikanska marknaden och nu genomförs en företrädesemission f...
Efter några år av trevande försäljning på selekterade marknader i EU riktar Prostatype Genomics nu fokus mot den mognare USA-marknaden.
Prostatype Genomics secured SEK 25m in growth capital in the latest right issue.
The next US step is to sign a certified lab partner.
Prostatype recorded SEK 0.4m in sales in the first quarter.
Prostatype Genomics has proposed a SEK 34.3m funding (new issue of shares with preferential rights for existing shareholders) which is guara...
Bra momentum i Prostatype med ett 10-tal kliniker som förbereder införande av gentestet i klinisk rutin.
Prostatype is making significant progress, with more than 10 Nordic clinics offering the Prostatype test to patients.
Analysguiden inleder bevakning av medicinteknikbolaget Prostatype med motiverat värde 3,7-6,1 kr.
Prostatype are making good European launch progress with clinical evaluations, ongoing evaluations and a pipeline of new evaluations.
Prostatype Genomics has secured a SEK 22.5m rights issue (pre-cost of some SEK 3.
Prostatype Genomics is progressing with the European launch and preparing ahead for the US launch.
The Prostatype Genomics Board has proposed a SEK 22.
Redeye initiates coverage of Prostatype Genomics, a company offering a prognostics test that supports the critical decision by prostate canc...
